UNCY logo

Unicycive Therapeutics Inc. (UNCY)

$3.70

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on UNCY

Market cap

$103064451

EPS

-1.7

P/E ratio

--

Price to sales

--

Dividend yield

--

Beta

1.902406

Price on UNCY

Previous close

$3.55

Today's open

$3.58

Day's range

$3.55 - $3.78

52 week range

$3.33 - $8.74

Profile about UNCY

CEO

Shalabh Gupta

Employees

21

Headquarters

Mountain View, CA

Exchange

NASDAQ Capital Market

Shares outstanding

27855257

Issue type

Common Stock

UNCY industries and sectors

Healthcare

Biotechnology & Life Sciences

News on UNCY

Unicycive Therapeutics Announces Third Quarter 2026 Financial Results and Provides Business Update

MOUNTAIN VIEW, Calif., Nov. 16, 2026 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (Nasdaq: UNCY), a biotechnology company developing therapies for patients with kidney disease, today announced its financial results for the third quarter ended September 30, 2026, and provided a business update.

news source

GlobeNewsWire • Nov 16, 2026

news preview

Unicycive Therapeutics to Present at the Guggenheim 3rd Annual Healthcare Innovation Conference

MOUNTAIN VIEW, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (Nasdaq: UNCY), a biotechnology company developing therapies for patients with kidney disease, today announced that Shalabh Gupta, M.D., Chief Executive Officer, will present at the Guggenheim 3rd Annual Healthcare Innovation Conference on Tuesday, November 10, 2026, at 2:30 p.m. ET.

news source

GlobeNewsWire • Nov 4, 2026

news preview

Levi & Korsinsky Reminds Unicycive Therapeutics Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of November 2, 2026 - UNCY

A securities class action alleges Unicycive Therapeutics resubmitted its oxylanthanum carbonate New Drug Application without ever inspecting its third-party manufacturer's facility for cGMP compliance. Pension funds, asset managers, and other fiduciaries that held UNCY during the Class Period may wish to evaluate lead plaintiff options. A securities class action alleges Unicycive Therapeutics resubmitted its oxylanthanum carbonate New Drug Application without ever inspecting its third-party manufacturer's facility for cGMP compliance. Pension funds, asset managers, and other fiduciaries that held UNCY during the Class Period may wish to evaluate lead plaintiff options.

news source

GlobeNewsWire • Nov 2, 2026

news preview

Bronstein, Gewirtz & Grossman LLC Urges Unicycive Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

New class action for Unicycive (UNCY) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 11/2/2026

news source

GlobeNewsWire • Nov 2, 2026

news preview

CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Unicycive Therapeutics (NASDAQ: UNCY) Investors of Securities Class Action Lawsuit Deadline on November 2, 2026

NEW YORK--(BUSINESS WIRE)---- $UNCY #ClassAction--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (NASDAQ: UNCY) and reminds investors of the November 2, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Geor.

news source

Business Wire • Nov 2, 2026

news preview

DEADLINE ALERT for Hims & Hers Health, Inc. (HIMS), Unicycive Therapeutics, Inc. (UNCY), and Papa John's International, Inc. (PZZA): The Law Offices of Frank R. Cruz Reminds Investors of Lead Plaintiff Deadlines in Securities Fraud Class Actions

Investors in Hims & Hers Health, Inc., Unicycive Therapeutics, Inc., and Papa John's International, Inc. have upcoming deadlines to seek lead plaintiff appointment in pending securities class actions Investors in Hims & Hers Health, Inc., Unicycive Therapeutics, Inc., and Papa John's International, Inc. have upcoming deadlines to seek lead plaintiff appointment in pending securities class actions

news source

GlobeNewsWire • Nov 2, 2026

news preview

UNCY UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Unicycive Therapeutics (UNCY) Investors of Securities Class Action Lawsuit Deadline on November 2, 2026

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Unicycive To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Unicycive between December 29, 2025 and June 29, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - October 31, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Unicycive Therapeutics, Inc. ("Unicycive" or the "Company") (NASDAQ: UNCY) and reminds investors of the November 2, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

news source

Newsfile Corp • Oct 31, 2026

news preview

UNCY URGENT DEADLINE: Unicycive Therapeutics, Inc. Investors Have Until November 2nd to Contact Bragar Eagel & Squire, P.C. Seeking Lead Plaintiff Role

Bragar Eagel & Squire, P.C.  Litigation Partner  Brandon Walker  Encourages Investors Who Suffered Losses In Unicycive (UNCY) To Contact Him Directly To Discuss Their Options

news source

GlobeNewsWire • Oct 31, 2026

news preview

Unicycive Therapeutics: 95% Upside Priced Against A Wall Of Dilution And Regulatory Risk

Unicycive Therapeutics is rated Buy, with a risk-adjusted fair value of $6.97 per share, nearly 95% upside from current prices. UNCY's lead drug, OLC, targets hyperphosphatemia in CKD dialysis patients, with a PDUFA date set for March 25, 2027, after resolving manufacturing issues. Despite $61.4M in cash, a likely capital raise for commercialization could possibly as much as double share count, heavily diluting shareholders.

news source

Seeking Alpha • Oct 31, 2026

news preview

UNCY CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds Unicycive Therapeutics (UNCY) Investors of Securities Class Action Lawsuit Deadline on November 2, 2026

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Unicycive To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Unicycive between December 29, 2025 and June 29, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - October 30, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Unicycive Therapeutics, Inc. ("Unicycive" or the "Company") (NASDAQ: UNCY) and reminds investors of the November 2, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

news source

Newsfile Corp • Oct 30, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Unicycive Therapeutics Inc.

Open an M1 investment account to buy and sell Unicycive Therapeutics Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in UNCY on M1